Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication

被引：0
|
作者：
Winner, Paul K. [1 ]
Singh, Rashmi B. Halker [2 ]
Cohen, Joshua M. [3 ]
Yang, Ronghua [3 ]
Yeung, Paul P. [3 ]
Ramirez Campos, Verena [4 ]
机构：
[1] Premiere Res Inst, W Palm Beach, FL USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Teva Pharmaceut, Frazer, PA USA
[4] Teva Pharmaceut, Buenos Aires, DF, Argentina
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O38
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Efficacy of fremanezumab in migraine patients who have failed at least one prior migraine preventive medication (vol 19, pg O40, 2018)
    McAllister, Peter
    Dodick, David W.
    Cohen, Joshua M.
    Yang, Ronghua
    Yeung, Paul P.
    Ramirez Campos, Verena
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [12] Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study
    Winner, P. K.
    Freeman, M. C.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 118 - 119
  • [13] Long-term efficacy of fremanezumab in chronic and episodic migraine patients who failed at least one prior migraine preventive medication: results of a 1-year study
    Winner, Paul K.
    Freeman, Marshall C.
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Blaiss, Cory
    CEPHALALGIA, 2019, 39 : 36 - 37
  • [14] Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study
    Winner, Paul K.
    Freeman, Marshall C.
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Ortega, Mario
    ANNALS OF NEUROLOGY, 2019, 86 : S168 - S169
  • [15] Long-Term Efficacy of Fremanezumab in Patients with Episodic Migraine and Chronic Migraine Who Failed at Least One Prior Migraine Preventive Medication: Results from 6-and 12-Month Studies
    Dougherty, Carrie
    Ning, Xiaoping
    Cohen, Joshua M.
    Yang, Ronghua
    Campos, Verena Ramirez
    Seminerio, Michael
    Silberstein, Stephen D.
    ANNALS OF NEUROLOGY, 2020, 88 : S154 - S155
  • [16] Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine
    Brandes, Jan Lewis
    Kudrow, David
    Yeung, Paul P.
    Sakai, Fumihiko
    Aycardi, Ernesto
    Blankenbiller, Tricia
    Grozinski-Wolff, Melissa
    Yang, Ronghua
    Ma, Yuju
    CEPHALALGIA, 2020, 40 (05) : 470 - 477
  • [17] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine: Interim Results of a One-Year Study
    Brandes, J.
    Yeung, P. P.
    Cohen, J. M.
    Gandhi, S. K.
    Fitzgerald, T.
    Yang, R.
    Ma, Y.
    Aycardi, E.
    HEADACHE, 2018, 58 : 170 - 170
  • [18] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine: Results of a 1-Year Study
    Brandes, J.
    Marmura, M. J.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    HEADACHE, 2019, 59 : 122 - 122
  • [19] EFFICACY AND IMPACT ON ACUTE MEDICATION USE AND DISABILITY WITH FREMANEZUMAB IN PATIENTS WITH MIGRAINE WHO HAD INADEQUATE RESPONSE TO ≥3 PRIOR MIGRAINE PREVENTIVE MEDICATION CLASSES: RESULTS OF THE RANDOMIZED, DOUBLE-BLIND PHASE 3B FOCUS STUDY
    Lambru, Giorgio
    Dhiraj, Dalbir
    Ning, Xiaoping
    Campos, Verena Ramirez
    Du, Evelyn
    Cohen, Joshua M.
    Matharu, Manjit
    CEPHALALGIA, 2020, 40 : 91 - 92
  • [20] Fremanezumab Efficacy in Migraine Patients With Prior Inadequate Response to ≥3 Preventive Migraine Medication Classes and Depressive Symptoms
    Pozo-Rosich, Patricia
    Campos, Verena Ramirez
    Barash, Steve
    Akcicek, Hasan
    Lyras, Leonidas
    Lampl, Christian
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 49 - 50
12345